Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study
- PMID: 19267712
- DOI: 10.1111/j.1463-1326.2008.00973.x
Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study
Abstract
Aim: Metformin is the most commonly prescribed oral agent used in the treatment of type 2 diabetes. It is effective at reducing glycosylated Haemoglobin (HbA1c) and decreasing microvascular and macrovascular disease. However, up to 25% of patients develop gastrointestinal side effects leading to cessation in 5-10% of users. Metformin XL (glucophage SR) is a once a day preparation that delays absorption, leading to decreased peak metformin concentrations. We hypothesised that the XL preparation of metformin would be better tolerated than the standard immediate release (IR) preparation leading to improved adherence to therapy.
Methods: In a retrospective observational study, we studied adherence and glycaemic control in patients prescribed metformin IR and XL preparations in Tayside, UK.
Results: Metformin XL was used by 137 patients during the study period. Overall adherence was greater in the XL group (80%) compared with the 10,772 patients in the IR group (72%, p = 0.0026). In the 40 patients who changed from metformin IR to metformin XL who had sufficient data to determine adherence, the adherence increased from 62% in the IR group to 81% in the XL group (p < 0.0001). This was associated with an HbA1c reduction from 9.1 to 8.4% (p = 0.0739, n = 29).
Conclusions: Metformin XL use is associated with increased adherence compared with the IR preparation, although the mechanism for this cannot be determined from this study. In patients intolerant of metformin IR the XL preparation should be considered.
Similar articles
-
Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes.Clin Ther. 2018 May;40(5):752-761.e2. doi: 10.1016/j.clinthera.2018.04.002. Epub 2018 May 3. Clin Ther. 2018. PMID: 29729957 Clinical Trial.
-
Improving Type 2 Diabetes Care with Extended-Release Metformin: Real-Life Insights from a Physician Educational Program.Endocr Metab Immune Disord Drug Targets. 2024;24(12):1422-1430. doi: 10.2174/0118715303294909240221102552. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38425116 Free PMC article.
-
Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.Clin Ther. 2003 Feb;25(2):515-29. doi: 10.1016/s0149-2918(03)80093-0. Clin Ther. 2003. PMID: 12749511 Clinical Trial.
-
Extended-release metformin hydrochloride. Single-composition osmotic tablet formulation.Treat Endocrinol. 2004;3(5):327-32. doi: 10.2165/00024677-200403050-00008. Treat Endocrinol. 2004. PMID: 15330682 Review.
-
Overview of metformin: special focus on metformin extended release.Expert Opin Pharmacother. 2012 Aug;13(12):1797-805. doi: 10.1517/14656566.2012.705829. Epub 2012 Jul 9. Expert Opin Pharmacother. 2012. PMID: 22775758 Review.
Cited by
-
Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus.Diabetol Metab Syndr. 2010 Mar 18;2:16. doi: 10.1186/1758-5996-2-16. Diabetol Metab Syndr. 2010. PMID: 20298568 Free PMC article.
-
Dose distribution and up-titration patterns of metformin monotherapy in patients with type 2 diabetes.Endocrinol Diabetes Metab. 2019 Dec 17;3(1):e00107. doi: 10.1002/edm2.107. eCollection 2020 Jan. Endocrinol Diabetes Metab. 2019. PMID: 31922032 Free PMC article.
-
Effect of Cost and Formulation on Persistence and Adherence to Initial Metformin Therapy for Type 2 Diabetes.Diabetes Care. 2020 Jun;43(6):e66-e67. doi: 10.2337/dc19-2426. Epub 2020 Apr 6. Diabetes Care. 2020. PMID: 32253222 Free PMC article. No abstract available.
-
Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia.J Diabetes. 2012 Dec;4(4):395-406. doi: 10.1111/j.1753-0407.2012.00220.x. J Diabetes. 2012. PMID: 22742083 Free PMC article.
-
Adherence to therapies in patients with type 2 diabetes.Diabetes Ther. 2013 Dec;4(2):175-94. doi: 10.1007/s13300-013-0034-y. Epub 2013 Aug 30. Diabetes Ther. 2013. PMID: 23990497 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials